The most common surgery for prostate cancer is a radical prostatectomy. This surgery involves taking out the entire prostate gland, some lymph nodes and other nearby tissue, like the seminal vesicles ...

Localized prostate cancer treatments include radical prostatectomy and focal therapy, with the latter targeting only cancerous areas to preserve healthy tissue. Focal therapy allows for active ...

—Findings from a recent study suggest that management of prostate cancer has improved in the last 2 decades, including a lower frequency of pathologic grade group 1 prostatectomies. The number of ...

ORLANDO, Fla. (Ivanhoe Newswire) - The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The average age of men who get diagnosed is ...

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime The average age at diagnosis is 67 Less than 1% of the 3.5 million men living with prostate cancer are expected to die from it ...

Prostate cancer is the most commonly diagnosed cancer in the UK, with more than 63,000 new cases each year. Yet for many men, understanding their treatment options remains far from straightforward ...

Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.

The journey through prostate cancer treatment marks a significant chapter in many men’s lives, with surgery often serving as a pivotal turning point toward recovery. While the removal of cancerous ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...

From 2010 to 2024, the rate of surgeries declined more than fivefold in patients with pathologic grade group 1 (pGG1) prostate cancer, a cohort study found. The small proportion that were performed ...

Advances in radiotherapy are rapidly transforming how prostate cancer is treated, offering patients more precise, less invasive options that can fit more easily around everyday life ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...